Addison Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Addison Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,300	Closed	-$4K	–	786
2026 Q1	$4K	Hold	1,300	–	–	﹤0.01%	753
2025 Q4	$1.96K	Hold	1,300	–	–	﹤0.01%	785
2025 Q3	$3.37K	Hold	1,300	–	–	﹤0.01%	739
2025 Q2	$3.52K	Hold	1,300	–	–	﹤0.01%	730
2025 Q1	$4.41K	Hold	1,300	–	–	﹤0.01%	685
2024 Q4	$5.36K	Buy	+1,300	New	+$5.13K	﹤0.01%	657

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Addison Advisors's ELDN Position: Q2 2026 in Review

Addison Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 1,300 shares — an estimated $4K sold.

Addison Advisors first reported a position in ELDN in Q4 2024 and held it in 6 quarters. The position peaked at $5.36K in Q4 2024. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Addison Advisors reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Addison Advisors sold 1,300 Eledon Pharmaceuticals shares in Q2 2026, an estimated $4K.
Addison Advisors first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Addison Advisors's Eledon Pharmaceuticals position peaked at $5.36K in Q4 2024.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.